耐火材料(行星科学)
医学
移植物抗宿主病
免疫学
移植
胃肠病学
肠道菌群
内科学
造血干细胞移植
粪便
炎症性肠病
粪便细菌疗法
疾病
免疫系统
进行性疾病
微生物群
结直肠癌
T细胞
出处
期刊:Blood
[Elsevier BV]
日期:2025-11-03
卷期号:146 (Supplement 1): 7780-7780
标识
DOI:10.1182/blood-2025-7780
摘要
Abstract Disruption of the intestinal microbiota plays a crucial role on the initial and development of graft-versus-host disease (GVHD). Fecal microbiota transplantation (FMT) is effective for refractory acute GVHD, but unclear for refractory chronic GVHD (cGVHD). To investigate the effect of FMT on refractory cGVHD and its underlying mechanism, 12 patients with refractory cGVHD received FMT via colonoscopy, and response evaluated at 12 weeks after FMT in this study. Of the 12 patients underwent FMT, 6 patients obtained response including 1 complete response and 5 partial responses. The patients with refractory cGVHD exhibited lower α-diversity, higher levels of Escherichia-Shigellaand Enterobacteriaceae. FMT increased gut microbial diversity, especially expanded short-chain fatty acids (SCFAs) producing bacteria, decreased Escherichia-Shigella and Enterobacteriaceae in the responding patients. Meanwhile, it elevated SCFAs levels in the fecal sample of responder group and promoting the expansion of peripheral CD4+CD127- regulatory T (Treg) cells. Colon pathology revealed that CD4+ T and CD19+ B cells infiltration were decreased and CD4+ Treg cells increased after FMT. By cohousing experiment, we confirmed that healthy donor microbiota alleviated cGVHD recipients through SCFAs-Treg cells axis. The current study suggest that FMT effectively ameliorates refractory cGVHD through SCFAs-Treg cells axis.
科研通智能强力驱动
Strongly Powered by AbleSci AI